ATR 258
Alternative Names: ATR-258Latest Information Update: 25 Jul 2024
At a glance
- Originator Atrogi
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 27 May 2024 Atrogi completes phase-I Attractive 2 trial in Type 2 diabetes mellitus (In volunteers) in Sweden (PO, Capsule, Liquid) (NCT06432673)
- 24 Apr 2024 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in Sweden (PO, Capsule) (NCT06432673)
- 24 Apr 2024 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in Sweden (PO, Liquid) (NCT06432673)